The forecast for cardiovascular system medicine sales in Japan, expressed in US Dollars PPP per capita, shows a steady decline from 2024 to 2028, starting at 69.2 in 2024 down to 68.4 by 2028. Compared to 2023 values, this indicates a gradual decrease in per capita expenditure. The year-on-year decrease is subtle but consistent, highlighting a downward trend with a compound annual growth rate (CAGR) that suggests an average decline over the forecasted five-year period.
Future trends to monitor include potential market impacts from Japan's aging population and advancements in cardiovascular healthcare technology. Additionally, government healthcare policies and economic conditions could further influence spending and market dynamics.
